10-Q: Sunshine Biopharma Reports Increased Revenue but Continues to Face Losses in Q3 2024

Sunshine Biopharma saw a significant increase in revenue during the third quarter of 2024, but the company still reported a net loss.

Summary

• Sunshine Biopharma reported a revenue increase of 42% for the three months ended September 30, 2024, reaching $8,435,178 compared to $5,957,668 in the same period of 2023.
• The company's gross profit for the quarter was $2,866,151, up from $1,990,256 in the prior year.
• General and administrative expenses increased to $3,972,504, up from $2,769,730, due to higher accounting, consulting, marketing, and salary costs.
• The company experienced a net loss of $1,197,803 for the quarter, compared to a net loss of $651,482 in the same quarter of 2023.
• For the nine months ended September 30, 2024, revenue increased by 54% to $25,279,291, compared to $16,412,586 in 2023.
• The company's gross profit for the nine-month period was $7,576,745, up from $5,771,125 in the prior year.
• General and administrative expenses for the nine-month period increased to $11,351,144, up from $9,369,203.
• The net loss for the nine-month period was $2,975,904, compared to a net loss of $3,256,020 in the same period of 2023.
• As of September 30, 2024, the company had cash and cash equivalents of $12,206,655.
• The company believes its current cash will be sufficient to fund operations for the next 24 months, but anticipates needing to raise additional capital in the future.

Sentiment

Score: 5

Explanation: The document presents a mixed picture. While revenue growth is strong, the company continues to incur losses and faces risks related to funding and drug development. The sentiment is neutral to slightly negative due to the ongoing losses.

Positives

• The company experienced a significant increase in revenue, both for the quarter and the nine-month period.
• Gross profit also increased, indicating improved profitability on sales.
• The company successfully completed a public offering, raising substantial capital.
• Nora Pharma is expanding its product portfolio with 32 new drugs planned for launch.
• The company has a pipeline of proprietary drugs in development, including K1.1 mRNA for liver cancer and SBFM-PL4 for SARS Coronavirus infections.
• The company has secured Health Canada approval for NIOPEG, a biosimilar drug.

Negatives

• The company continues to incur net losses, both for the quarter and the nine-month period.
• General and administrative expenses have increased significantly, impacting profitability.
• The company's research and development of Adva-27a has been paused due to unfavorable in vitro results.
• The company's cash used in operating activities increased compared to the same period last year.
• The company's cash used in investing activities increased compared to the same period last year.

Risks

• The company is not generating adequate revenues to fully implement its business plan.
• The company anticipates needing to raise additional capital in the future, which may not be available on acceptable terms.
• The company's drug development programs are subject to risks and uncertainties, including unfavorable results and regulatory hurdles.
• The company's generic drug sales are dependent on governmental policies in Canada, which may change over time.
• The company's reliance on a single geographic market (Canada) for its generic pharmaceutical sales exposes it to regional risks.

Future Outlook

The company believes its existing cash on hand will be sufficient to fund its pharmaceuticals sales operations and research and development activities for the next 24 months, but anticipates needing to raise additional capital in the future.

Management Comments

• The increase in revenue is attributable to expanded marketing and sales efforts by our wholly owned subsidiary, Nora Pharma.
• We believe the addition of these new products to our existing portfolio will strengthen our presence in the Canadian $9.7 billion a year generic drugs market and provide us with greater access to pharmacies as we become more of a go-to supplier for every-day and specialty medicines.

Industry Context

The company operates in the pharmaceutical industry, focusing on generic prescription drugs and over-the-counter products. The Canadian generic drug market is valued at $9.7 billion annually, and the company is expanding its product portfolio to increase its market share. The company is also involved in the development of novel therapeutics in oncology and antivirals, which are areas of significant unmet medical need.

Comparison to Industry Standards

• The company's revenue growth of 42% in Q3 and 54% for the nine-month period is strong compared to many established generic pharmaceutical companies, which typically see more modest growth rates.
• However, the company's continued net losses are a concern, as many established pharmaceutical companies are profitable.
• The company's R&D spending is relatively high for a company of its size, reflecting its focus on developing novel therapeutics, which is not typical for generic drug manufacturers.
• The company's reliance on the Canadian market is a risk, as many larger pharmaceutical companies have a more diversified geographic presence.
• Compared to companies like Teva Pharmaceuticals or Mylan (now Viatris), which are major players in the generic drug market, Sunshine Biopharma is much smaller and has a less diversified product portfolio.

Related Party Transactions

• The Company paid $400,000 to Advanomics Corporation, a company controlled by the CEO of the Company.

Stakeholder Impact

• Shareholders may be concerned about the continued net losses and the need for additional capital.
• Employees may be impacted by the company's financial performance and future funding decisions.
• Customers (pharmacies) may benefit from the company's expanded product portfolio.
• Suppliers may be impacted by the company's financial performance and future funding decisions.
• Creditors may be impacted by the company's financial performance and future funding decisions.

Next Steps

• The company plans to launch 32 additional generic prescription drugs in late 2024 and 2025.
• The company will continue to conduct xenograft experiments on K1.1 mRNA-LNP.
• The company will continue to develop an injectable drug candidate of first-in-class PLpro inhibitor to treat SARS-CoV2.
• The company will continue to seek additional funding.

Key Dates

Keywords

pharmaceuticals, generic drugs, oncology, antivirals, mRNA, Nora Pharma, revenue, net loss, public offering, drug development, Canada, warrants